The effects of cytochrome P450 2D6 inhibitors on a high-dose tramadol taper for medically supervised opioid withdrawal: a retrospective chart review

References

• Rudd RA, Seth P, David F, Scholl L. Increases in drug and opioid-involved overdose deaths - united states, 2010–2015. MMWR Morb Mortal Wkly Rep. 2016;65(50–51):1445–52. doi:10.15585/mmwr.mm655051e1.
   PubMed Web of Science ®Google Scholar
• HCUP Fast Stats. Healthcare cost and utilization project (HCUP); 2018. [accessed 2018 Jun 1]. www.hcup-us.ahrq.gov/faststats/opioid/opioiduse.jsp.
   Google Scholar
• Radcliff JA, Vellanki SC, Moore PS, Weisensell BJ, Cather JK. A retrospective chart review of outcomes resulting from a three-day tramadol taper for acute opioid withdrawal. J Addict Dis. 2018;37(3–4):252–8. doi:10.1080/10550887.2019.1668743.
   PubMed Web of Science ®Google Scholar
• Chawla JM, Pal H, Lal R, Jain R, Schooler N, Balhara YP. Comparison of efficacy between buprenorphine and tramadol in the detoxification of opioid (heroin)-dependent subjects. J Opioid Manage. 2013;9(1):35–41. doi:10.5055/jom.2013.0145.
   PubMedGoogle Scholar
• Lofwall MR, Babalonis S, Nuzzo PA, Siegel A, Campbell C, Walsh SL. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend. 2013;133(1):188–97. doi:10.1016/j.drugalcdep.2013.05.010.
   PubMed Web of Science ®Google Scholar
• Dunn KE, Tompkins DA, Bigelow GE, Strain EC. Efficacy of tramadol extended-release for opioid withdrawal: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):885–93. doi:10.1001/jamapsychiatry.2017.1838.
   PubMed Web of Science ®Google Scholar
• Threlkeld M, Parran TV, Adelman CA, Grey SF, Yu J. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study. Am J Addict. 2006;15(2):186–91. doi:10.1080/10550490500528712.
   PubMed Web of Science ®Google Scholar
• Tamaskar R, Parran TV, Jr, Heggi A, Brateanu A, Rabb M, Yu J. Tramadol versus buprenorphine for the treatment of opiate withdrawal: a retrospective cohort control study. J Addict Dis. 2003;22(4):5–12. doi:10.1300/j069v22n04_02.
   PubMed Web of Science ®Google Scholar
• Zarghami M, Masoum B, Shiran MR. Tramadol versus methadone for treatment of opiate withdrawal: a double-blind, randomized, clinical trial. J Addict Dis. 2012;31(2):112–7. doi:10.1080/10550887.2012.665728.
   PubMed Web of Science ®Google Scholar
• Ziaaddini H, Ziaaddini A, Asghari N, Nakhaee N, Eslami M. Trial of tramadol plus gabapentin for opioid detoxification. Iran Red Crescent Med J. 2015;17(1):e18202. doi:10.5812/ircmj.18202.
   PubMed Web of Science ®Google Scholar
• Sobey PW, Parran TV, Jr, Grey SF, Adelman CL, Yu J. The use of tramadol for acute heroin withdrawal: a comparison to clonidine. J Addict Dis. 2004;22(4):13–25. doi:10.1300/J069v22n04_03.
   Web of Science ®Google Scholar
• Ultram (tramadol hydrochloride) [package insert]. Titusville, NJ: Janssen Pharmaceutical Companies; 2003.
   Google Scholar
• Subrahmanyam V, Renwick AB, Walters DG, et al. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab Dispos. 2001;29(8):1146–55.
   PubMed Web of Science ®Google Scholar
• Haage P, Kronstrand R, Josefsson M, Calistri S, van Schaik RHN, Green H, Kugelberg FC. Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of CYP2D6, CYP2B6, and CYP3A4 genotype. Pharmacol Res Perspect. 2018;6(4):e00419. doi:10.1002/prp2.419.
   PubMed Web of Science ®Google Scholar
• Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GAPJM, van Schaik RHN, Schalekamp T, Touw DJ, et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther. 2011;89(5):662–73. doi:10.1038/clpt.2011.34.
   PubMed Web of Science ®Google Scholar
• Dean L. Tramadol therapy and CYP2D6 genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information (US); 2012.
   Google Scholar
• Allegaert K, Holford N, Anderson BJ, Holford S, Stuber F, Rochette A, Trocóniz IF, Beier H, de Hoon JN, Pedersen RS, et al. Tramadol and o-desmethyl tramadol clearance maturation and disposition in humans: a pooled pharmacokinetic study. Clin Pharmacokinet. 2015;54(2):167–78. doi:10.1007/s40262-014-0191-9.
   PubMed Web of Science ®Google Scholar
• Bastami S, Haage P, Kronstrand R, Kugelberg FC, Zackrisson AL, Uppugunduri S. Pharmacogenetic aspects of tramadol pharmacokinetics and pharmacodynamics after a single oral dose. Forensic Sci Int. 2014;238:125–32. doi:10.1016/j.forsciint.2014.03.003.
   PubMed Web of Science ®Google Scholar
• Dong H, Lu SJ, Zhang R, Liu DD, Zhang YZ, Song CY. Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients. Eur J Clin Pharmacol. 2015;71(6):681–6. doi:10.1007/s00228-015-1857-4.
   PubMed Web of Science ®Google Scholar
• Garrido MJ, Sayar O, Segura C, Rapado J, Dios-Viéitez MC, Renedo MJ, Trocóniz IF. Pharmacokinetic/pharmacodynamic modeling of the antinociceptive effects of (+)-tramadol in the rat: Role of cytochrome P450 2D activity. J Pharmacol Exp Ther. 2003;305(2):710–8. doi:10.1124/jpet.102.047779.
   PubMed Web of Science ®Google Scholar
• Coller JK, Michalakas JR, James HM, Farquharson AL, Colvill J, White JM, Somogyi AA. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. Br J Clin Pharmacol. 2012;74(5):835–41. doi:10.1111/j.1365-2125.2012.04256.x.
   PubMed Web of Science ®Google Scholar
• Saarikoski T, Saari TI, Hagelberg NM, Backman JT, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K. Effects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadol. Eur J Clin Pharmacol. 2015;71(3):321–7. doi:10.1007/s00228-014-1799-2.
   PubMed Web of Science ®Google Scholar
• Laugesen S, Enggaard TP, Pedersen RS, Sindrup SH, Brosen K. Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol. Clin Pharmacol Ther. 2005;77(4):312–23. doi:10.1016/j.clpt.2004.11.002.
   PubMed Web of Science ®Google Scholar
• Nielsen AG, Pedersen RS, Noehr-Jensen L, Damkier P, Brosen K. Two separate dose-dependent effects of paroxetine: Mydriasis and inhibition of tramadol's O-demethylation via CYP2D6. Eur J Clin Pharmacol. 2010;66(7):655–60. doi:10.1007/s00228-010-0803-8.
   PubMed Web of Science ®Google Scholar
• Frost DA, Soric MM, Kaiser R, Neugebauer RE. Efficacy of tramadol for pain management in patients receiving strong cytochrome P450 2D6 inhibitors. Pharmacotherapy. 2019;39(6):724–9. doi:10.1002/phar.2269.
   PubMed Web of Science ®Google Scholar
• Flockhart D. Drug interactions: cytochrome P450 drug interaction table. Bloomington: Indiana University, Department of Medicine. Clinical Pharmacology Website. [accessed 2019 Jun 1]. http://medicine.iupui.edu/clinpharm/ddis/table.aspx. Published 2007. Updated 2016.
   Google Scholar
• Perez TE, Mealey KL, Grubb TL, Greene SA, Court MH. Tramadol metabolism to O-desmethyl tramadol (M1) and N-desmethyl tramadol (M2) by dog liver microsomes: Species comparison and identification of responsible canine cytochrome P-450s (CYPs). Drug Metab Dispos. 2016;44(12):1963–72. doi:10.1124/dmd.116.071902.
   PubMed Web of Science ®Google Scholar
• Saarikoski T, Saari TI, Hagelberg NM, Neuvonen M, Neuvonen PJ, Scheinin M, Olkkola KT, Laine K. Rifampicin markedly decreases the exposure to oral and intravenous tramadol. Eur J Clin Pharmacol. 2013;69(6):1293–301. doi:10.1007/s00228-012-1460-x.
   PubMed Web of Science ®Google Scholar
• Dossing M, Pilsgaard H, Rasmussen B, Poulsen HE. Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism. Eur J Clin Pharmacol. 1983;25(2):215–22. doi:10.1007/bf00543794.
   PubMed Web of Science ®Google Scholar